156 related articles for article (PubMed ID: 19341816)
1. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution.
Vergoni AV; Tosi G; Tacchi R; Vandelli MA; Bertolini A; Costantino L
Nanomedicine; 2009 Dec; 5(4):369-77. PubMed ID: 19341816
[TBL] [Abstract][Full Text] [Related]
2. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
3. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
4. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
5. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration.
Tahara K; Miyazaki Y; Kawashima Y; Kreuter J; Yamamoto H
Eur J Pharm Biopharm; 2011 Jan; 77(1):84-8. PubMed ID: 21074612
[TBL] [Abstract][Full Text] [Related]
6. How Nanoparticle Physicochemical Parameters Affect Drug Delivery to Cells in the Retina via Systemic Interactions.
You Q; Sokolov M; Grigartzik L; Hintz W; van Wachem BGM; Henrich-Noack P; Sabel BA
Mol Pharm; 2019 Dec; 16(12):5068-5075. PubMed ID: 31609624
[TBL] [Abstract][Full Text] [Related]
7. Distribution of β-carotene-encapsulated polysorbate 80-coated poly(D, L-lactide-co-glycolide) nanoparticles in rodent tissues following intravenous administration.
Miyazawa T; Nakagawa K; Harigae T; Onuma R; Kimura F; Fujii T; Miyazawa T
Int J Nanomedicine; 2015; 10():7223-30. PubMed ID: 26664113
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
10. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters.
Gelperina S; Maksimenko O; Khalansky A; Vanchugova L; Shipulo E; Abbasova K; Berdiev R; Wohlfart S; Chepurnova N; Kreuter J
Eur J Pharm Biopharm; 2010 Feb; 74(2):157-63. PubMed ID: 19755158
[TBL] [Abstract][Full Text] [Related]
11. Intranasal and intravenous administration of octa-arginine modified poly(lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide.
O'Donnell A; Moollan A; Baneham S; Ozgul M; Pabari RM; Cox D; Kirby BP; Ramtoola Z
J Pharm Pharmacol; 2015 Apr; 67(4):525-36. PubMed ID: 25515568
[TBL] [Abstract][Full Text] [Related]
12. Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery.
Kulkarni SA; Feng SS
Pharm Res; 2013 Oct; 30(10):2512-22. PubMed ID: 23314933
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting.
Md S; Ali M; Baboota S; Sahni JK; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2014 Feb; 40(2):278-87. PubMed ID: 23369094
[TBL] [Abstract][Full Text] [Related]
14. Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?
Tosi G; Badiali L; Ruozi B; Vergoni AV; Bondioli L; Ferrari A; Rivasi F; Forni F; Vandelli MA
Nanomedicine (Lond); 2012 Mar; 7(3):365-82. PubMed ID: 21957863
[TBL] [Abstract][Full Text] [Related]
15. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration.
Wen Z; Yan Z; He R; Pang Z; Guo L; Qian Y; Jiang X; Fang L
Drug Deliv; 2011 Nov; 18(8):555-61. PubMed ID: 21812752
[TBL] [Abstract][Full Text] [Related]
16. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol-PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: in vitro and in vivo evaluations.
Hu X; Yang F; Liao Y; Li L; Zhang L
Drug Deliv; 2017 Nov; 24(1):121-132. PubMed ID: 28156159
[TBL] [Abstract][Full Text] [Related]
18. Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles.
Yadav KS; Chuttani K; Mishra AK; Sawant KK
PDA J Pharm Sci Technol; 2011; 65(2):131-9. PubMed ID: 21502074
[TBL] [Abstract][Full Text] [Related]
19. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
Gan CW; Feng SS
Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable polymeric nanoparticles administered in the cerebrospinal fluid: Brain biodistribution, preferential internalization in microglia and implications for cell-selective drug release.
Peviani M; Capasso Palmiero U; Cecere F; Milazzo R; Moscatelli D; Biffi A
Biomaterials; 2019 Jul; 209():25-40. PubMed ID: 31026609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
